Use of a lentiviral flap vector for induction of CTL immunity against melanoma. Perspectives for immunotherapy

Journal of Gene Medicine

Volumn 4, Issue 1, 2002, Pages 38-45

  Firat, Hüseyin ^a,b   Zennou, Véronique ^c   Garcia Pons, Francisco ^a   Ginhoux, Florent ^b   Cochet, Madeleine ^a   Danos, Olivier ^b   Lemonnier, François A ^a   Langlade Demoyen, Pierre ^a   Charneau, Pierre ^c  

^a CNRS   (France)

^b GÉNÉTHON   (France)

^c INSTITUT PASTEUR   (France)

Author keywords

Cancer immunotherapy; CTL; Dendritic cells; HIV 1 vector; Melanoma

Indexed keywords

GLYCOPROTEIN GP 100; HLA A2 ANTIGEN; LENTIVIRUS VECTOR; MELAN A; MELANOMA ANTIGEN 3; MONOPHENOL MONOOXYGENASE; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FLUORESCENCE ACTIVATED CELL SORTING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOTHERAPY; IN VITRO STUDY; MELANOMA; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM; ANIMAL; ANTIGEN PRESENTATION; CYTOTOXICITY; GENE EXPRESSION REGULATION; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGY; METHODOLOGY; TRANSGENIC MOUSE;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS MUSCULUS;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; GENE EXPRESSION REGULATION; GENETIC VECTORS; HIV; HUMANS; IMMUNOTHERAPY; MELANOMA; MICE; MICE, TRANSGENIC; T-LYMPHOCYTES, CYTOTOXIC; TRANSDUCTION, GENETIC;

EID: 0036371235     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jgm.243     Document Type: Article

References (27)

1. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Med 1998; 4: 328-332.
2. de Gruiji TD, Curiel DT. Cancer vaccine strategies get bigger and better. Nature Med 1999; 5: 1124-1125.
3. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD Jr. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 1996; 183: 283-287.
4. Song W, Kong HL, Carpenter H, et al. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J Exp Med 1997; 186: 1247-1256.
5. Thurner B, Haendle I, Roder C, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999; 190: 1669-1678.
6. Ludewig B, Oehen S, Barchiesi F, et al. Protective antiviral cytotoxic T cell memory is most efficiently maintained by restimulation via dendritic cells. J Immunol 1999; 163: 1839-1844.
7. Naldini L, Blomer U, Gage FH, Trono D, Verma IM. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA 1996; 93: 11382-11388.
8. Naldini L. Lentiviruses as gene transfer agents for delivery to non-dividing cells. Curr Opin Biotech 1998; 9: 457-463.
9. Zufferey R, Dull T, Mandel RJ, et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998; 72: 9873-9880.
10. Zennou V, Petit C, Guetard D, et al. HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 2000; 101 173-185.
11. Charneau P, Mirambeau G, Roux P, et al. HIV-1 reverse transcription. A termination step at the center of the genome. J Mol Biol 1994; 241: 651-662.
12. Follenzi A, Ailles LE, Bakovic S, Geuna M, Naldini L. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nature Genet 2000; 25: 217-222.
13. Sirven A, Pflumio F, Zennou V, et al. The human immunodeficiency virus type-1 central DNA flap is a crucial determinant for lentiviral vector nuclear import and gene transduction of human hematopoietic stem cells. Blood 2000; 96: 4103-4110.
14. Firat H, Garcia-Pons F, Tourdot S, et al. H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies. Eur J Immunol 1999; 29: 3112-3121.
15. Mateo L, Gardner J, Chen Q, et al. An HLA-A2 polyepitope vaccine for melanoma immunotherapy. J Immunol 1999; 163: 4058-4063.
16. Pascolo S, Bervas N, Ure JM, et al. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 1997; 185: 2043-2051.
17. Valmori D, Dutoit V, Lienard D, et al. Tetramer-guided analysis of TCR beta-chain usage reveals a large repertoire of melan-A-specific CD8 + T cells in melanoma patients. J Immunol 2000; 165: 533-538.
18. Bousso P, Casrouge A, Altman JD, et al. Individual variations in the murine T cell response to a specific peptide reflect variability in naïve repertoires. Immunity 1998; 9: 169-178.
19. Inaba K, Inaba M, Deguchi M, et al. Granulocytes, macrophages, and dendritic cells arise from a common major histocompatibility complex class II-negative progenitor in mouse bone marrow. Proc Natl Acad Sci USA 1993; 90: 3038-3042.
20. Goxe B, Latour N, Bartholeyns J, Romet-Lemonne JL, Chokri M. Monocyte-derived dendritic cells: development of a cellular processor for clinical applications. Res Immunol 1998; 149: 643-646.
21. Song ES, Lee V, Surh CD, et al. Antigen presentation in retroviral vector-mediated gene transfer in vivo. Proc Natl Acad Sci U S A 1997: 94: 1943-1948.
22. Specht JM, Wang G, Do MT, et al. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J Exp Med 1997; 186: 1213-1221.
23. Zitvogel L, Mayordomo JI, Tjandrawan T, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996; 183: 87-97.
24. Warner JF, Jolly DJ, Merritt J. Human immunodeficiency virus immunotherapy using a retroviral vector. Curr Top Microbiol Immunol 1998; 226: 145-160.
25. Kafri T, Blomer U, Peterson DA, Gage FH, Verma IM. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nature Genet 1997; 17: 314-317.
26. Gruber A, Kan-Mitchell J, Kuhen KL, Mukai T, Wong-Staal F. Dendritic cells transduced by multiply deleted HIV-1 vectors exhibit normal phenotypes and functions and elicit an HIV-specific cytotoxic T-lymphocyte response in vitro. Blood 2000; 96: 1327-1333.
27. Schroers R, Sinha I, Segall H, et al. Transduction of human PBMC-derived dendritic cells and macrophages by an HIV-1-based lentiviral vector system. Mol Ther 2000; 1: 171-179.